Watermark
  Back to Search Results

BGB-A317-311

Completed

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-311

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03957590

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20190198

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / 75 Years

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / 75 Years

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan